{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:04:55Z","timestamp":1761156295079,"version":"build-2065373602"},"reference-count":108,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Gaucher\u2019s disease (GD) is the most frequently inherited lysosomal storage disease, presenting both visceral and neurologic symptoms. Mutations in acid \u03b2-glucocerebrosidase disrupt the sphingolipid catabolic pathway promoting glucosylceramide (GlcCer) accumulation in lysosomes. Current treatment options are enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). However, neither of these approaches is effective in treating the neurological aspect of the disease. The use of small pharmacological compounds that act as molecular chaperones is a promising approach that is still experimental. In recent years, an association between GD and Parkinson like synucleinopathies has been discovered. Since 1992, a number of mouse models of GD have been the developed and partially reproduce phenotype of the disease. More recently, the discovery of direct reprograming has allowed the derivation of induced pluripotent stem cells (iPSc) from fibroblasts obtained from GD patients. iPSc can be expanded indefinitely in vitro and differentiated to macrophages and neurons, the main relevant cell types involved in GD. In this work, we review iPSc models of GD and summarize what we have learned from this system.<\/jats:p>","DOI":"10.3390\/ijms18040888","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T10:59:30Z","timestamp":1492772370000},"page":"888","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Induced Pluripotent Stem Cell Modeling of Gaucher\u2019s Disease: What Have We Learned?"],"prefix":"10.3390","volume":"18","author":[{"given":"Dino","family":"Santos","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences and Medicine, University of Algarve, Faro 8005-139, Portugal"},{"name":"Center for Biomedical Research, University of Algarve, Faro 8005-139, Portugal"}]},{"given":"Gustavo","family":"Tiscornia","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Medicine, University of Algarve, Faro 8005-139, Portugal"},{"name":"Center for Biomedical Research, University of Algarve, Faro 8005-139, Portugal"},{"name":"Cl\u00ednica EUGIN, Barcelona 08028, Spain"}]}],"member":"1968","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"key":"ref_1","unstructured":"Butler, G.A.G. (2001). Glucosylceramide lipidosis\u2014Gaucher disease. The Online Metabolic and Molecular Bases of Inherited Diseases, McGraw-Hill. [8th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/mds.24945","article-title":"Hyposmia and Cognitive Impairment in Gaucher Disease Patients and Carriers","volume":"27","author":"McNeill","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","article-title":"Phenotypic continuum in neuronopathic gaucher disease: An intermediate phenotype between type 2 and type 3","volume":"143","author":"Schiffmann","year":"2003","journal-title":"J. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5858\/2008-132-851-GDROTL","article-title":"Gaucher disease: Review of the literature","volume":"132","author":"Chen","year":"2008","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.256.5058.794","article-title":"Gaucher disease: New molecular approaches to diagnosis and treatment","volume":"256","author":"Beutler","year":"1992","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000131781","article-title":"Regional assignment of the structural gene for human acid \u03b2-glucosidase to q42\u2192qter on chromosome 1","volume":"33","author":"Devine","year":"1982","journal-title":"Cytogenet. Genome Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF00279398","article-title":"Assignment of the gene coding for human \u03b2-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies","volume":"64","author":"Barneveld","year":"1983","journal-title":"Hum. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/sj.embor.embor873","article-title":"X-ray structure of human acid-\u03b2-glucosidase, the defective enzyme in Gaucher disease","volume":"4","author":"Dvir","year":"2003","journal-title":"EMBO Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S \u03b2-glucosidase: A therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tem.2004.05.003","article-title":"Pharmacological chaperones: Potential treatment for conformational diseases","volume":"15","author":"Bernier","year":"2004","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and Classification of 304 Mutant Alleles in Patients with Type 1 and Type 3 Gaucher Disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1021\/jm300063b","article-title":"Discovery, Structure\u2013Activity Relationship, and Biological Evaluation of Noninhibitory Small Molecule Chaperones of Glucocerebrosidase","volume":"55","author":"Patnaik","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4137\/PMC.S2332","article-title":"Chaperone therapy for neuronopathic lysosomal diseases: competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities","volume":"3","author":"Suzuki","year":"2009","journal-title":"Perspect. Medicin. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000324116","article-title":"Congenital Ichthyosis in Severe Type II Gaucher Disease with a Homozygous Null Mutation","volume":"100","author":"Haverkaemper","year":"2011","journal-title":"Neonatology"},{"key":"ref_16","first-page":"273","article-title":"Gaucher Disease: Insights from a Rare Mendelian Disorder","volume":"14","author":"Sidransky","year":"2012","journal-title":"Discov. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher\u2019s disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14861","DOI":"10.1016\/S0021-9258(18)82412-7","article-title":"Human acid \u03b2-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity","volume":"268","author":"Grace","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity","volume":"14","author":"Ron","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.1209038","article-title":"The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation","volume":"334","author":"Walter","year":"2011","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molmed.2011.05.003","article-title":"Exploring the link between glucocerebrosidase mutations and Parkinsonism","volume":"17","author":"Westbroek","year":"2011","journal-title":"Trends Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","article-title":"LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of \u03b2-Glucocerebrosidase","volume":"131","author":"Reczek","year":"2007","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","article-title":"Gaucher Disease and Its Treatment Options","volume":"47","author":"Bennett","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1021\/jm301557k","article-title":"Pharmacological Chaperones as Therapeutics for Lysosomal Storage Diseases","volume":"56","author":"Boyd","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11696","DOI":"10.1002\/anie.201505147","article-title":"pH-Responsive Pharmacological Chaperones for Rescuing Mutant Glycosidases","volume":"54","author":"Narita","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1073\/pnas.87.6.2334","article-title":"Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease","volume":"87","author":"Fink","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1073\/pnas.0606016103","article-title":"Effective cell and gene therapy in a murine model of Gaucher disease","volume":"103","author":"Enquist","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","first-page":"S21","article-title":"Prevalence of Parkinson\u2019s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group","volume":"54","author":"Launer","year":"2000","journal-title":"Neurology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/0891988710383572","article-title":"The Genetics of Parkinson Disease","volume":"23","author":"Bekris","year":"2010","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneur.58.2.186","article-title":"Synucleinopathies: Clinical and Pathological Implications","volume":"58","author":"Galvin","year":"2001","journal-title":"Arch. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cell.2005.09.028","article-title":"\u03b1-Synuclein Cooperates with CSP\u03b1 in Preventing Neurodegeneration","volume":"123","author":"Chandra","year":"2005","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.parkreldis.2006.03.002","article-title":"Parkinson\u2019s disease and family history","volume":"12","author":"Sellbach","year":"2006","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1126\/science.274.5290.1197","article-title":"Mapping of a Gene for Parkinson\u2019s Disease to Chromosome 4q21-q23","volume":"274","author":"Polymeropoulos","year":"1996","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-Synuclein Gene Identified in Families with Parkinson\u2019s Disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10545-010-9055-0","article-title":"The risk of Parkinson\u2019s disease in type 1 Gaucher disease","volume":"33","author":"Bultron","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/jnnp.48.2.172","article-title":"Neurological involvement in type 1 (adult) Gaucher\u2019s disease","volume":"48","author":"McKeran","year":"1985","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Salvayre, R., and Douste-Blazy, L. (1988). Parkinsonian Symptomatology in a Patient with Type I (Adult) Gaucher\u2019s Disease. Lipid Storage Disorders: Biological and Medical Aspects, Springer.","DOI":"10.1007\/978-1-4613-1029-7"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/mgme.2001.3201","article-title":"Gaucher Disease and Parkinsonism: A Phenotypic and Genotypic Characterization","volume":"73","author":"Tayebi","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ymgme.2011.06.008","article-title":"Aggregation of \u03b1-synuclein in brain samples from subjects with glucocerebrosidase mutations","volume":"104","author":"Choi","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ymgme.2004.04.011","article-title":"Neuropathology provides clues to the pathophysiology of Gaucher disease","volume":"82","author":"Wong","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Schiffmann","year":"2004","journal-title":"J. Med. Genet."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bcmd.2006.02.004","article-title":"Increased incidence of Parkinson disease among relatives of patients with Gaucher disease","volume":"36","author":"Halperin","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa033277","article-title":"Mutations in the Glucocerebrosidase Gene and Parkinson\u2019s Disease in Ashkenazi Jews","volume":"351","author":"Rosenbaum","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/mds.20319","article-title":"Analysis of the glucocerebrosidase gene in Parkinson\u2019s disease","volume":"20","author":"Sato","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1212\/01.wnl.0000196492.80676.7c","article-title":"Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population","volume":"66","author":"Toft","year":"2006","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/archneur.64.7.1056","article-title":"Glucocerebrosidase mutations and risk of parkinson disease in chinese patients","volume":"64","author":"Tan","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/archneurol.2007.68","article-title":"Glucocerebrosidase Gene Mutations: A Risk Factor for Lewy Body Disorders","volume":"65","author":"Mata","year":"2008","journal-title":"Arch. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson\u2019s Disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archneurol.2009.72","article-title":"Mutations for gaucher disease confer high susceptibility to Parkinson disease","volume":"66","author":"Mitsui","year":"2009","journal-title":"Arch. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/hmg\/ddq454","article-title":"Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson\u2019s disease","volume":"20","author":"Lesage","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1126\/science.1176056","article-title":"MafB\/c-Maf Deficiency Enables Self-Renewal of Differentiated Functional Macrophages","volume":"326","author":"Aziz","year":"2009","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11910-013-0368-x","article-title":"The Association Between \u03b2-Glucocerebrosidase Mutations and Parkinsonism","volume":"13","author":"Swan","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1471-4159.2012.07879.x","article-title":"Glucocerebrosidase Mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease","volume":"123","author":"Hanson","year":"2012","journal-title":"J. Neurochem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson\u2019s disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-291X(75)90286-7","article-title":"The Gaucher mouse","volume":"67","author":"Kanfer","year":"1975","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1471-4159.1978.tb12395.x","article-title":"The Gaucher Mouse: Differential Action of Conduritol B Epoxide and Reversibility of its Effects","volume":"30","author":"Stephens","year":"1978","journal-title":"J. Neurochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2008.01.013","article-title":"Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid \u03b2-glucosidase residual activity levels","volume":"94","author":"Xu","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/BF02537244","article-title":"Glucosylceramide and the Level of the Glucosidase-Stimulating Proteins","volume":"21","author":"Datta","year":"1986","journal-title":"Lipids"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/mthe.2002.0650","article-title":"Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model","volume":"6","author":"Marshall","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/357407a0","article-title":"Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene","volume":"357","author":"Tybulewicz","year":"1992","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1203\/00006450-199210000-00023","article-title":"Gaucher Disease in the Neonate: A Distinct Gaucher Phenotype Is Analogous to a Mouse Model Created by Targeted Disruption of the Glucocerebrosidase Gene","volume":"32","author":"Sidransky","year":"1992","journal-title":"Pediatr. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF02962142","article-title":"A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse","volume":"24","author":"Willemsen","year":"1995","journal-title":"Mol. Chem. Neuropathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1172\/JCI117160","article-title":"Consequences of \u03b2-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease","volume":"93","author":"Holleran","year":"1994","journal-title":"J. Clin. Investig."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10038-004-0155-2","article-title":"Down-regulation of Bcl-2 in the fetal brain of the Gaucher disease mouse model: A possible role in the neuronal loss","volume":"49","author":"Hong","year":"2004","journal-title":"J. Hum. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/emm.2006.41","article-title":"Downregulation of neurotrophic factors in the brain of a mouse model of Gaucher disease: Implications for neuronal loss in Gaucher disease","volume":"38","author":"Kim","year":"2006","journal-title":"Exp. Mol. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3346\/jkms.2006.21.4.733","article-title":"Upregulation of Proinflammatory Cytokines in the Fetal Brain of the Gaucher Mouse","volume":"21","author":"Hong","year":"2006","journal-title":"J. Korean Med. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1073\/pnas.95.5.2503","article-title":"Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure (SIMP)","volume":"95","author":"Liu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI0214530","article-title":"Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage","volume":"109","author":"Mizukami","year":"2002","journal-title":"J. Clin. Invest."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","article-title":"Viable Mouse Models of Acid \u03b2-Glucosidase Deficiency : The Defect in Gaucher Disease","volume":"163","author":"Xu","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects \u03b1-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Dai, M., Liou, B., Swope, B., Wang, X., Zhang, W., Inskeep, V., Grabowski, G.A., Sun, Y., and Pan, D. (2016). Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162367"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Mu, T.W.W., Fowler, D.M., and Kelly, J.W. (2008). Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol., 6.","DOI":"10.1371\/journal.pbio.0060026"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ymgme.2008.12.008","article-title":"Diltiazem. A L-type Ca2+ channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells","volume":"96","author":"Rigat","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Sun, Y., Liou, B., Quinn, B., Ran, H., Xu, Y.H., and Grabowski, G.A. (2009). In Vivo and Ex Vivo Evaluation of L-Type Calcium Channel Blockers on Acid \u03b2-Glucosidase in Gaucher Disease Mouse Models. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0007320"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/auto.6.5.12047","article-title":"Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease","volume":"6","author":"Sun","year":"2010","journal-title":"Autophagy"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Xu, Y.H., Jia, L., Quinn, B., Zamzow, M., Stringer, K., Aronow, B., Sun, Y., Zhang, W., Setchell, K.D.R., and Grabowski, G.A. (2011). Global gene expression profile progression in Gaucher disease mouse models. BMC Genom., 12.","DOI":"10.1186\/1471-2164-12-20"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"McEachern","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10545-010-9072-z","article-title":"Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy","volume":"33","author":"Marshall","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/jgm.901","article-title":"AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease","volume":"8","author":"McEachern","year":"2006","journal-title":"J. Gene Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1634\/stemcells.2008-0844","article-title":"Successful Low-Risk Hematopoietic Cell Therapy in a Mouse Model of Type 1 Gaucher Disease","volume":"27","author":"Enquist","year":"2009","journal-title":"Stem Cells"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"19473","DOI":"10.1073\/pnas.1003308107","article-title":"Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage","volume":"107","author":"Mistry","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2006.09.008","article-title":"Generation of a conditional knockout of murine glucocerebrosidase: Utility for the study of Gaucher disease","volume":"9","author":"Sinclair","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1073\/pnas.0708086104","article-title":"Murine models of acute neuronopathic Gaucher disease","volume":"104","author":"Enquist","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/hmg\/ddr019","article-title":"Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease","volume":"20","author":"Vitner","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12015-015-9622-8","article-title":"Choices for Induction of Pluripotency: Recent Developments in Human Induced Pluripotent Stem Cell Reprogramming Strategies","volume":"12","author":"Brouwer","year":"2016","journal-title":"Stem Cell Rev."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Tiscornia, G., Vivas, E., and Belmonte, J. (2011). Diseases in a dish: Modeling human genetic disorders using induced pluripotent cells. Nat. Med., 1570\u20131576.","DOI":"10.1038\/nm.2504"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cell.2010.10.016","article-title":"A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells","volume":"143","author":"Marchetto","year":"2010","journal-title":"Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1126\/science.1158799","article-title":"Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons","volume":"321","author":"Dimos","year":"2008","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature07677","article-title":"Induced pluripotent stem cells from a spinal muscular atrophy patient","volume":"457","author":"Ebert","year":"2009","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nature08129","article-title":"Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells","volume":"460","author":"Raya","year":"2009","journal-title":"Nature"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa0908679","article-title":"Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome","volume":"363","author":"Moretti","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/nyas.13052","article-title":"Disease models for the development of therapies for lysosomal storage diseases","volume":"1371","author":"Xu","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher Disease Glucocerebrosidase and \u03b1-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.1520335113","article-title":"\u03b1-Synuclein\u2013induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models","volume":"113","author":"Mazzulli","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"18054","DOI":"10.1073\/pnas.1207889109","article-title":"Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease","volume":"109","author":"Panicker","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/stem.1732","article-title":"Gaucher iPSC-Derived Macrophages Produce Elevated Levels of Inflammatory Mediators and Serve as a New Platform for Therapeutic Development","volume":"32","author":"Panicker","year":"2014","journal-title":"Stem Cells"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1093\/hmg\/ddv297","article-title":"Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells","volume":"24","author":"Awad","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1038\/ncomms5028","article-title":"iPSC-Derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis","volume":"5","author":"Aureli","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Sun, Y., Florer, J., Mayhew, C.N., Jia, Z., Zhao, Z., Xu, K., Ran, H., Liou, B., Zhang, W., and Setchell, K.D.R. (2015). Properties of Neurons Derived from Induced Pluripotent Stem Cells of Gaucher Disease Type 2 Patient Fibroblasts: Potential Role in Neuropathology. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118771"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A New Glucocerebrosidase Chaperone Reduces \u03b1-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/13543776.2011.569162","article-title":"Pharmacological chaperone therapy for Gaucher disease: A patent review","volume":"21","author":"Benito","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1039\/C6CC01564F","article-title":"Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: Lessons from Gaucher, GM1-gangliosidosis and Fabry diseases","volume":"52","author":"Mellet","year":"2016","journal-title":"Chem. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/hmg\/dds471","article-title":"Neuronopathic Gaucher\u2019s disease: Induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds","volume":"22","author":"Tiscornia","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"240ra73","DOI":"10.1126\/scitranslmed.3008659","article-title":"Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs","volume":"6","author":"Aflaki","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","article-title":"ER Stress and Autophagic Perturbations Lead to Elevated Extracellular \u03b1-Synuclein in GBA-N370S Parkinson\u2019s iPSC-Derived Dopamine Neurons","volume":"6","author":"Fernandes","year":"2016","journal-title":"Stem Cell Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of \u03b2-Glucocerebrosidase Reduces Pathological \u03b1-Synuclein and Restores Lysosomal Function in Parkinson\u2019s Patient Midbrain Neurons","volume":"36","author":"Mazzulli","year":"2016","journal-title":"J. Neurosci."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/4\/888\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:33:11Z","timestamp":1760207591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/4\/888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":108,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4]]}},"alternative-id":["ijms18040888"],"URL":"https:\/\/doi.org\/10.3390\/ijms18040888","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2017,4,21]]}}}